BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ReCor Medical Reports Impressive Six-Month Follow-Up Data for Its Ultrasound-Based PARADISE™ Renal Denervation System for Treating Resistant Hypertension


6/15/2012 11:10:52 AM

RONKONKOMA, N.Y., June 15, 2012—ReCor Medical, an emerging medical device company, reported today six-month follow-up data on eight patients who have been treated via renal denervation for their resistant hypertension with the Company’s PARADISE® System—the only system for renal denervation that is based on ultrasound, not radiofrequency, energy.

At six months follow-up, the PARADISE data showed that office systolic blood pressure was reduced by an average of 33 mm Hg in 8 patients. Of note: there were also significant and sustained blood pressure reductions in home and ambulatory measurements at six months. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

“These clinical results strongly suggest a significant competitive advantage for ReCor’s ultrasound-based PARADISE?system compared to radiofrequency-based standard of care for treating resistant hypertension patients,” said Mano Iyer, CEO, ReCor Medical.

The PARADISE ultrasound catheter was designed with the aim to allow complete circumferential denervation more consistently and efficiently than the standard of care radiofrequency ablation catheter. The procedure with the PARADISE system only requires 30 seconds of energy delivery per treatment location, thereby dramatically reducing the overall procedure time.

ReCor also announced that it has published a collection of video interviews conducted during ‘EuroPCR 2012’ with key opinion leaders (KOLs) on the topic of RENAL DENERVATION to treat resistant hypertension. (Click link above to see these videos.)

About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology. ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company’s PARADISE™ technology for renal denervation is CE-marked. For more information about ReCor Medical, please visit the Company’s website at www.recormedical.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES